Laminin γ2–mediating T cell exclusion attenuates response to anti–PD-1 therapy
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Laminin γ2–mediating T cell exclusion attenuates response to anti–PD-1 therapy
Authors
Keywords
-
Journal
Science Advances
Volume 7, Issue 6, Pages eabc8346
Publisher
American Association for the Advancement of Science (AAAS)
Online
2021-02-04
DOI
10.1126/sciadv.abc8346
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Cancer-associated fibroblasts-derived gamma-glutamyltransferase 5 promotes tumor growth and drug resistance in lung adenocarcinoma
- (2020) Jia-Ru Wei et al. Aging-US
- Unique Biological Activity and Potential Role of Monomeric Laminin-γ2 as a Novel Biomarker for Hepatocellular Carcinoma: A Review
- (2019) Hiroshi Yasuda et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- α-PD-1 therapy elevates Treg/Th balance and increases tumor cell pSmad3 that are both targeted by α-TGFβ antibody to promote durable rejection and immunity in squamous cell carcinomas
- (2019) E. Dodagatta-Marri et al. Journal for ImmunoTherapy of Cancer
- HN1L-mediated transcriptional axis AP-2γ/METTL13/TCF3-ZEB1 drives tumor growth and metastasis in hepatocellular carcinoma
- (2019) Lei Li et al. CELL DEATH AND DIFFERENTIATION
- Transforming Growth Factor-β Signaling in Immunity and Cancer
- (2019) Eduard Batlle et al. IMMUNITY
- Targeting Protein Kinases to Enhance the Response to anti-PD-1/PD-L1 Immunotherapy
- (2019) Marilina García-Aranda et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Anti-PD-1 versus anti-PD-L1 therapy in patients with pretreated advanced non-small-cell lung cancer: a meta-analysis
- (2019) Alfredo Tartarone et al. Future Oncology
- A Phase 2 Study of Galunisertib (TGF-β1 Receptor Type I Inhibitor) and Sorafenib in Patients With Advanced Hepatocellular Carcinoma
- (2019) R.K. Kelley et al. Clinical and Translational Gastroenterology
- One checkpoint may hide another: inhibiting the TGFβ signaling pathway enhances immune checkpoint blockade
- (2019) Aditi Gupta et al. Hepatobiliary Surgery and Nutrition
- Albumin–globulin ratio is a predictive biomarker of antitumor effect of anti-PD-1 antibody in patients with non-small cell lung cancer
- (2019) Yu Nakanishi et al. International Journal of Clinical Oncology
- The Evolving Landscape of Biomarkers for Anti-PD-1 or Anti-PD-L1 Therapy
- (2019) Antje Tunger et al. Journal of Clinical Medicine
- Prediction of response to anti-PD-1 therapy in patients with non-small-cell lung cancer by electronic nose analysis of exhaled breath
- (2019) R de Vries et al. ANNALS OF ONCOLOGY
- Anti-PD-1 immunotherapy in advanced esophageal squamous cell carcinoma: A long-awaited breakthrough finally arrives
- (2019) Hung-Yang Kuo et al. JOURNAL OF THE FORMOSAN MEDICAL ASSOCIATION
- LncRNA CASC9 promotes esophageal squamous cell carcinoma metastasis through upregulating LAMC2 expression by interacting with the CREB-binding protein
- (2018) Yan Liang et al. CELL DEATH AND DIFFERENTIATION
- TGF-β Inhibition and Immunotherapy: Checkmate
- (2018) Karuna Ganesh et al. IMMUNITY
- TcR-α recombinations in renal cell carcinoma exome files correlate with an intermediate level of T-cell exhaustion biomarkers
- (2018) Anne T. Mai et al. INTERNATIONAL IMMUNOLOGY
- TGFβ drives immune evasion in genetically reconstituted colon cancer metastasis
- (2018) Daniele V. F. Tauriello et al. NATURE
- Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational Burden
- (2018) Matthew D. Hellmann et al. NEW ENGLAND JOURNAL OF MEDICINE
- TSPAN15 interacts with BTRC to promote oesophageal squamous cell carcinoma metastasis via activating NF-κB signaling
- (2018) Baozhu Zhang et al. Nature Communications
- Treatment of Advanced Non–Small Cell Lung Cancer in 2018
- (2018) Deborah B. Doroshow et al. JAMA Oncology
- Targeting the TGFβ pathway with galunisertib, a TGFβRI small molecule inhibitor, promotes anti-tumor immunity leading to durable, complete responses, as monotherapy and in combination with checkpoint blockade
- (2018) Rikke B. Holmgaard et al. Journal for ImmunoTherapy of Cancer
- TGFβ attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells
- (2018) Sanjeev Mariathasan et al. NATURE
- Signatures of T cell dysfunction and exclusion predict cancer immunotherapy response
- (2018) Peng Jiang et al. NATURE MEDICINE
- Expansion of cancer stem cell pool initiates lung cancer recurrence before angiogenesis
- (2018) Lei Li et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Targeting TGF ‐β signaling in Liver Cancer
- (2018) Shuyun Rao et al. HEPATOLOGY
- Recovery of T-cell receptor V(D)J recombination reads from lower grade glioma exome files correlates with reduced survival and advanced cancer grade
- (2018) Boris I. Chobrutskiy et al. JOURNAL OF NEURO-ONCOLOGY
- TGFβ Blockade Augments PD-1 Inhibition to Promote T-Cell Mediated Regression of Pancreatic Cancer
- (2018) Daniel R Principe et al. MOLECULAR CANCER THERAPEUTICS
- Profiling Preexisting Antibodies in Patients Treated With Anti–PD-1 Therapy for Advanced Non–Small Cell Lung Cancer
- (2018) Yukihiro Toi et al. JAMA Oncology
- Overexpression of LAMC2 predicts poor prognosis in colorectal cancer patients and promotes cancer cell proliferation, migration, and invasion
- (2017) Dandan Huang et al. TUMOR BIOLOGY
- Regulation of the Immune Response by TGF-β: From Conception to Autoimmunity and Infection
- (2017) Shomyseh Sanjabi et al. Cold Spring Harbor Perspectives in Biology
- Role of TGF-β-induced Claudin-4 expression through c-Jun signaling in non-small cell lung cancer
- (2016) Girish Rachakonda et al. CELLULAR SIGNALLING
- Laminin-332 sustains chemoresistance and quiescence as part of the human hepatic cancer stem cell niche
- (2016) Olivier Govaere et al. JOURNAL OF HEPATOLOGY
- Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer
- (2016) Martin Reck et al. NEW ENGLAND JOURNAL OF MEDICINE
- Coordinated integrin activation by actin-dependent force during T-cell migration
- (2016) Pontus Nordenfelt et al. Nature Communications
- LAMC2 enhances the metastatic potential of lung adenocarcinoma
- (2015) Y W Moon et al. CELL DEATH AND DIFFERENTIATION
- Alpha2beta1 integrin promotes T cell survival and migration through the concomitant activation of ERK/Mcl-1 and p38 MAPK pathways
- (2014) Dalila Naci et al. CELLULAR SIGNALLING
- Laminin-5γ-2 (LAMC2) Is Highly Expressed in Anaplastic Thyroid Carcinoma and Is Associated With Tumor Progression, Migration, and Invasion by Modulating Signaling of EGFR
- (2013) Manoj Garg et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Opposing roles for RhoH GTPase during T-cell migration and activation
- (2012) C. M. Baker et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Expression of laminin 5-γ2 chain in cutaneous squamous cell carcinoma and its role in tumour invasion
- (2011) H Hamasaki et al. BRITISH JOURNAL OF CANCER
- Immunohistochemical analysis of laminin 5-γ2 chain expression for differentiation of basal cell carcinoma from trichoblastoma
- (2011) Haruka Hamasaki et al. HISTOPATHOLOGY
- Rac Activation by the T-Cell Receptor Inhibits T Cell Migration
- (2010) Eva Cernuda-Morollón et al. PLoS One
- TGFβ in Cancer
- (2008) Joan Massagué CELL
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started